Drug-Induced Aseptic Meningitis with Amoxicillin; Restless Legs Syndrome Associated with Escitalopram; Toxic Epidermal Necrolysis with Fluoxetine; Serotonin Syndrome Precipitated by Amantadine Therapy and Renal Failure; Sunitinib and Allergic Interstitial Nephritis; Two Separate Reports of Adverse Drug Reactions with Duloxetine

2008 ◽  
Vol 43 (4) ◽  
pp. 261-264
Author(s):  
Joel Shuster
Keyword(s):  
Renal Failure ◽  
Toxic Epidermal Necrolysis ◽  
Aseptic Meningitis ◽  
Adverse Drug Reactions ◽  
Interstitial Nephritis ◽  
Restless Legs Syndrome ◽  
Serotonin Syndrome ◽  
Drug Reactions ◽  
Drug Induced ◽  
Restless Legs

Adverse Drug Reactions: Drug-Induced Toxic Epidermal Necrolysis

1994 ◽  
Vol 7 (2) ◽  
pp. vi-viii
Author(s):  
Debra J. Olsen ◽  
Julienne K. Kirk ◽  
Patricia Flores-Runk
Keyword(s):  
Toxic Epidermal Necrolysis ◽  
Adverse Drug Reactions ◽  
Drug Reactions ◽  
Drug Induced

Adverse drug reactions in anaesthesia

2017 ◽  
Author(s):  
Philip M. Hopkins
Keyword(s):  
Malignant Hyperthermia ◽  
Adverse Drug Reactions ◽  
Serotonin Syndrome ◽  
Plasma Cholinesterase ◽  
Drug Reactions ◽  
Drug Induced ◽  
Perioperative Morbidity ◽  
Acute Porphyrias ◽  
Serotonergic Drugs ◽  
Patients Experience

Adverse drug reactions are implicated in more than 40% of anaesthesia-related deaths. Undoubtedly, many more patients experience morbidity from adverse drug reactions. Widely cited definitions of adverse drug reactions encompass common side-effects but this chapter focuses on those that are unexpected reactions to drugs administered by anaesthetists and that occur at normal drug doses. The chapter includes a comprehensive account of malignant hyperthermia, which remains a major contributor to anaesthesia related to deaths. Malignant hyperthermia is a pharmacogenetic condition triggered by potent inhalational anaesthetics and possibly also suxamethonium. The genetic basis, pathophysiology, clinical presentations, and management of malignant hyperthermia are discussed. The chapter covers two other pharmacogenetic conditions: the acute porphyrias and butyrylcholinesterase (plasma cholinesterase) deficiency. Drug-induced anaphylaxis is another cause of perioperative morbidity and mortality. Recent data indicate that anaphylaxis during anaesthesia may be much more common than previously thought. The other type of adverse drug reaction covered in the chapter is serotonin syndrome. Perioperative serotonin syndrome is most likely to occur when patients who are already taking serotonergic drugs, such as selective serotonin reuptake inhibitor antidepressants or ‘triptan’ antimigraine treatments, are given a second drug with serotonergic properties, such as tramadol.

scholarly journals Intravenous N-acetylcysteine in severe cutaneous drug reaction treatment: A case series

2020 ◽  
Vol 8 ◽  
pp. 2050313X2093470 ◽  
Author(s):  
Md Jahidul Hasan ◽  
Raihan Rabbani
Keyword(s):  
Toxic Epidermal Necrolysis ◽  
Intravenous Immunoglobulin ◽  
Adverse Drug Reactions ◽  
Therapeutic Option ◽  
Case Series ◽  
High Rate ◽  
Stevens Johnson Syndrome ◽  
Drug Reactions ◽  
Drug Induced ◽  
Johnson Syndrome

Drug-induced serious adverse reaction is an unpleasant event with high rate of mortality. Stevens–Johnson Syndrome and toxic epidermal necrolysis are most common among the serious adverse drug reactions. There is no selective drug therapy for the management of serious adverse drug reactions-associated mucocutaneous blisters. The use of N-acetylcysteine in the treatment of mucocutaneous blisters has limited evidence worldwide. Three cases of toxic epidermal necrolysis or Stevens–Johnson Syndrome-associated mucocutaneous blisters are presented in this study where intravenous N-acetylcysteine (600 mg, every 8 h) was given in early hospitalization hours for the treatment of mucocutaneous fluid-filled blisters. Here, one patient with toxic epidermal necrolysis received intravenous immunoglobulin along with intravenous N-acetylcysteine and the other two patients (toxic epidermal necrolysis/Stevens–Johnson Syndrome) received only N-acetylcysteine intravenously. In response, mucocutaneous fluid-filled blisters stopped progressing within 48 h and were healed within 2 weeks of admission in the intensive care unit. Thus, intravenous N-acetylcysteine with or without having intravenous immunoglobulin in the treatment of serious adverse drug reactions-associated mucocutaneous blisters may be an effective therapeutic option for better clinical outcome.

Toxic Epidermal Necrolysis with Levofloxacin; Serotonin Syndrome Associated with Linezolid; Severe Hypokalemia Seen with Dicloxacillin Therapy; Terfinabine Hepatotoxicity

2002 ◽  
Vol 37 (9) ◽  
pp. 913-916 ◽  
Author(s):  
Joel Shuster
Keyword(s):  
Toxic Epidermal Necrolysis ◽  
Adverse Drug Reactions ◽  
Serotonin Syndrome ◽  
Drug Reactions

The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), to discuss methods of prevention, and to promote reporting of ADRs to the FDA's medWatch program (800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.

scholarly journals Piperacillin/tazobactam induced toxic epidermal necrolysis and drug induced liver injury

2018 ◽  
Vol 5 (2) ◽  
pp. 460
Author(s):  
Hardeep S. Deep ◽  
Mohit Kumar ◽  
Barjinder Pal Singh ◽  
Nisha Kajla
Keyword(s):  
Drug Reaction ◽  
Case Report ◽  
Liver Injury ◽  
Toxic Epidermal Necrolysis ◽  
Adverse Drug Reactions ◽  
Drug Reactions ◽  
Drug Induced ◽  
Biochemical Characteristics ◽  
Drug Induced Liver Injury ◽  
Ultimate Outcome

The liver and skin are the organs most commonly involved in serious adverse drug reactions. Rarely a drug reaction can affect both organs concurrently. The association of drug induced liver injury (DILI) and toxic epidermal necrolysis (TEN) is even rarer and may be rarely reported. This is a case report on development of both TEN and DILI following use of piperacillin / tazobactam. We describe our experience of DILI occurring in association with TEN including the etiological agent responsible, its clinical/ biochemical characteristics and ultimate outcome.

scholarly journals Severe Adverse Drug Reactions to Quetiapine in Two Patients Carrying CYP2D6*4 Variants: A Case Report

2021 ◽  
Vol 22 (12) ◽  
pp. 6480
Author(s):  
Céline K. Stäuble ◽  
Markus L. Lampert ◽  
Thorsten Mikoteit ◽  
Martin Hatzinger ◽  
Kurt E. Hersberger ◽  
...  
Keyword(s):  
Cytochrome P450 ◽  
Case Report ◽  
Adverse Drug Reactions ◽  
Active Metabolite ◽  
Hepatic Metabolism ◽  
Cytochrome P450 3A4 ◽  
Drug Reactions ◽  
Drug Induced ◽  
Potential Impact ◽  
Intermediate Metabolizer

We report two cases of patients who developed severe adverse drug reactions including persistent movement disorders, nausea, and vertigo during treatment with quetiapine at maximum daily doses ranging between 300 and 400 mg. The extensive hepatic metabolism of quetiapine is mainly attributed to cytochrome P450 3A4 (CYP3A4). However, there is recent evidence supporting the idea of CYP2D6 playing a role in the clearance of the quetiapine active metabolite norquetiapine. Interestingly, both patients we are reporting of are carriers of the CYP2D6*4 variant, predicting an intermediate metabolizer phenotype. Additionally, co-medication with a known CYP2D6 inhibitor and renal impairment might have further affected quetiapine pharmacokinetics. The herein reported cases could spark a discussion on the potential impact of a patient’s pharmacogenetic predisposition in the treatment with quetiapine. However, further studies are warranted to promote the adoption of pharmacogenetic testing for the prevention of drug-induced toxicities associated with quetiapine.

Drug-Induced Restless Legs Syndrome

2018 ◽  
Vol 52 (7) ◽  
pp. 662-672 ◽  
Author(s):  
Edna Patatanian ◽  
Melanie K. Claborn
Keyword(s):  
Restless Legs Syndrome ◽  
English Language ◽  
Case Reports ◽  
Data Extraction ◽  
Case Series ◽  
Predisposing Factors ◽  
Drug Induced ◽  
Restless Legs ◽  
Drug Classes ◽  
Study Selection

Objective: To review the literature on drug-induced restless legs syndrome (DI-RLS). Data Sources: The review included a search for English-language literature from 1966 to December 2017 in the MEDLINE, PubMed, and Ovid databases using the following search terms: restless legs syndrome (RLS), periodic limb movement, adverse effects, and drug-induced. In addition, background articles on the pathophysiology, etiology, and epidemiology of RLS were retrieved. Bibliographies of relevant articles were reviewed for additional citations. Study Selection and Data Extraction: All case reports, case series, and review articles of DI-RLS were identified and analyzed. There were only a small number of controlled clinical trials, and most data were from case reports and case series. Results: Several drugs and drug classes have been implicated in DI-RLS, with antidepressants, antipsychotics, and antiepileptics having the most evidence. In addition, RLS may be linked with a number of disorders or underlying predisposing factors as well. Conclusions: The prevalence of RLS is variable and ranges from 3% to 19% in the general population. There are many predisposing factors to RLS, but an emerging body of evidence suggests that there is an association between numerous drugs and RLS.

Lower limb flexor reflex: Comparisons between drug-induced akathisia and restless legs syndrome

2017 ◽  
Vol 641 ◽  
pp. 40-44 ◽  
Author(s):  
Aysegul Gunduz ◽  
Baris Metin ◽  
Sinem Zeynep Metin ◽  
Burc Cagri Poyraz ◽  
Derya Karadeniz ◽  
...  
Keyword(s):  
Restless Legs Syndrome ◽  
Lower Limb ◽  
Drug Induced ◽  
Flexor Reflex ◽  
Restless Legs
Sign in / Sign up

Export Citation Format

Share Document